Compositions and methods for modulating HEXM1 expression

US10959966B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10959966-B2
Application numberUS-201515115132-A
CountryUS
Kind codeB2
Filing dateJan 30, 2015
Priority dateJan 30, 2014
Publication dateMar 30, 2021
Grant dateMar 30, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The potency of a series of Hexamethylene bis-acetamide (HMBA) derivatives of formula I, that induce Hexamethylene bis-acetamide inducible protein 1 (HEXIM1) was determined in cancer cells. The method of inducing HEXIM1 expression and cell differentiation in cancer and HIV cells are disclosed. Optimization of HMBA analogs that are symmetrical and unsymmetrical are also discussed.

First claim

Opening claim text (preview).

Having described the invention, we claim: 1. A method of inducing hexamethylene bis-acetamide inducible protein 1 (HEXIM1) expression in at least one of breast cancer cells and/or prostate cancer cells of a subject, comprising: administering to the cancer cells of the subject a compound having the formula: R 7 is selected from the group consisting of substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heterocycloalkenyl containing from 5-6 ring atoms, heteroaryl or heterocyclyl containing from 5-14 ring atoms, C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, C 1 -C 24 alkoxy, C 2 -C 24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, and (—O-acyl); R 8 is a linear or branched C 1 -C 12 alkyl group; and pharmaceutically acceptable salts thereof. 2. The method of claim 1 , wherein the compound is administered in vitro, in vivo and/or ex vivo to the breast cancer cells and/or prostate cancer cells of the subject. 3. The method of claim 1 , wherein the compound has the formula: wherein n 1 is 1-7, R 9 is an electron donating or withdrawing group selected from the group consisting of OH, OMe, OAc, CN, NO 2 , halo, —(CH 2 )n 3 CH 3 (n 2 =0-7), phenyl, benzyl, SO 2 , SO 3 , alkylsulfonyl, amine, alkylamino, and carboxyl, and pharmaceutically acceptable salts thereof. 4. The method of claim 1 , wherein the compound has the formula:

Assignees

Inventors

Classifications

  • A61K31/16Primary

    Amides, e.g. hydroxamic acids · CPC title

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

  • A61K31/18Primary

    Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63) · CPC title

  • Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10959966B2 cover?
The potency of a series of Hexamethylene bis-acetamide (HMBA) derivatives of formula I, that induce Hexamethylene bis-acetamide inducible protein 1 (HEXIM1) was determined in cancer cells. The method of inducing HEXIM1 expression and cell differentiation in cancer and HIV cells are disclosed. Optimization of HMBA analogs that are symmetrical and unsymmetrical are also discussed.
Who is the assignee on this patent?
Univ Case Western Reserve
What technology area does this patent fall under?
Primary CPC classification A61K31/16. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).